Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

• Status: Completed
• Trial end date: 2017-05-18
• Target enrollment: 0
• Participant gender: All

Summary

Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center at Tyler
• Collaborator: Abbott
• Treatments: Clarithromycin

Criteria

Inclusion Criteria:

• Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; absence of other potential lung pathogens (except for the coexistence of M. abscessus)

• Age 18 years and older

Exclusion Criteria:

• History of macrolide allergy

• Must not receive the antihistamines terfenadine (Seldane) or astemizole (Hismanal) while on clarithromycin

• Children less than 18 years of age

• If a menstruating female, not pregnant and on adequate birth control